Study of Prophylaxis, ACtivity and Effectiveness (SPACE) in Hemophilia Patients Currently Treated With ADVATE or RIXUBIS

CompletedOBSERVATIONAL
Enrollment

64

Participants

Timeline

Start Date

July 22, 2014

Primary Completion Date

March 29, 2016

Study Completion Date

March 29, 2016

Conditions
Hemophilia AHemophilia B
Interventions
BIOLOGICAL

ADVATE (Antihemophilic Factor [Recombinant])

BIOLOGICAL

RIXUBIS (Coagulation Factor IX [Recombinant])

Trial Locations (17)

11021

North Shore/Long Island Jewish PRIME, Great Neck

19104

Children's Hospital of Philadelphia, Philadelphia

21205

Johns Hopkins University School Of Medicine, Baltimore

28210

The Presbyterian Hospital, Charlotte

37232

The Vanderbilt Clinic, Nashville

40504

University of Kentucky Medical Center, Lexington

48201

Childrens Hospital of Michigan, Detroit

48823

Michigan State University, East Lansing

49684

Munson Medical Center, Traverse City

61615

Bleeding and Clotting Disorders Institute, Peoria

64108

Children's Mercy Hospitals & Clinics, Kansas City

78550

The University of Texas MD Anderson, Harlingen

80045

University of Colorado, Aurora

90007

Orthopaedic Hospital DBA Orthopaedic Hemophilia Treatment Center, Los Angeles

92123

Rady Childrens Hospital, San Diego

97239

Oregon Health & Science University, Portland

98104

Puget Sound Blood Center, Seattle

All Listed Sponsors
lead

Baxalta now part of Shire

INDUSTRY

NCT02190149 - Study of Prophylaxis, ACtivity and Effectiveness (SPACE) in Hemophilia Patients Currently Treated With ADVATE or RIXUBIS | Biotech Hunter | Biotech Hunter